Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Advanced Medical Solutions ( (GB:AMS) ) has shared an update.
Advanced Medical Solutions Group plc reported strong performance for the year ending December 2024, following the acquisitions of Syntacoll and Peters Surgical. The integration of these acquisitions has enhanced the company’s market reach and product offerings, leading to expected full-year revenues of approximately £177 million and EBITDA between £40.0 to £40.5 million. The strategic initiatives in the Woundcare business are aimed at improving margins in 2025, reinforcing the Group’s competitive position. CEO Chris Meredith expressed optimism about the synergistic benefits from the acquisitions, projecting growth and opportunities in the coming year.
More about Advanced Medical Solutions
Advanced Medical Solutions Group plc (AMS) is a world-leading developer and manufacturer of tissue-healing technologies. The company offers a range of surgical products, such as tissue adhesives, sutures, haemostats, internal fixation devices, and sealants under various brands including LiquiBand®, RESORBA®, and LIQUIFIX™. Additionally, AMS provides wound care dressings through its ActivHeal® brand. With a global presence, AMS operates through a network of distributors and direct sales forces, and has R&D hubs in several countries.
YTD Price Performance: -3.54%
Average Trading Volume: 483,612
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £408.6M
Learn more about AMS stock on TipRanks’ Stock Analysis page.
